Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 69.
- You have advanced triple-negative breast cancer (meaning it does not have receptors for HER2, estrogen, or progesterone) that has spread to the bones.
- You have not had any prior treatment for advanced disease, though you may have had chemotherapy or immunotherapy for early-stage cancer if enough time has passed since treatment ended.
- You are generally active and able to care for yourself (ECOG score 0-1).
- You do not have serious health conditions like active infections, heart problems, or uncontrolled autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs—sacituzumab tirumotecan and anlotinib—for people with triple-negative breast cancer that has spread or cannot be removed by surgery and has already been treated with at least one prior therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
This trial tests a new drug called LBL-024, either alone or with other medicines, for people with triple negative breast cancer. It aims to see if the drug can shrink tumors and how safe it is.
This Phase 2 trial compares two chemotherapy combinations to see which works better for advanced triple-negative breast cancer. You would be asked to join one treatment arm based on study assignment and be followed for response and side effects.
This trial studies whether adding pembrolizumab (an immunotherapy) to standard chemotherapy after surgery can improve outcomes for people with early-stage triple-negative breast cancer. The treatment you receive depends on the level of immune cells (TILs) found in your tumor.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
This trial tests a combination of three drugs (lenvatinib, sindilimab, and nab-paclitaxel) as a first treatment for advanced triple-negative breast cancer that has come back or spread. The goal is to see if this combination is safe and effective.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.